

AMENDMENTS TO THE CLAIMS

Claim 1. (Currently amended) The isolated peptide sequence GGIGDGG [~~SEQ ID NO. 4~~] (SEQ ID NO:2).

Claim 2. (Currently amended) An angiogenic composition comprising at least one peptide ~~chosen from the group consisting of IGD [SEQ ID NO. 1], IGDS [SEQ ID NO. 2], IGDD [SEQ ID NO. 3] and~~ including the sequence GGIGDGG [SEQ ID NO. 4] (SEQ ID NO:2), and at least one angiogenic growth factor other than said at least one peptide.

Claim 3. (Currently amended) The angiogenic composition of claim 2 wherein said other at least one angiogenic growth factor is chosen from the group consisting of bone-derived angiogenic proteins ~~proteins~~ (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF- α), transforming growth factor-beta (TGF- β), and tumor necrosis factor-alpha (TNF- α).

Claim 4. (Currently amended) ~~An~~ The angiogenic composition of claim 2 wherein said at least one angiogenic growth factor comprises a recombinant angiogenic growth factor comprising at least one cell migration stimulating peptide chosen from the group consisting of IGD [SEQ ID NO. 1], IGDS [SEQ ID NO. 2], IGDD [SEQ ID NO. 3], and GGIGDGG [SEQ ID NO. 4], and at least one recombinant angiogenic growth factor.

Claim 5. (Currently amended) A composition that is active for promoting cell migration and/or angiogenesis under cell growth promoting conditions, the composition comprising at least one peptide ~~chosen from the group consisting of IGD [SEQ ID NO. 1], IGDS [SEQ ID NO. 2], IGDD [SEQ ID NO. 3], and~~ including the sequence GGIGDGG [SEQ ID NO. 4] (SEQ ID NO:2), and a matrix material.

Claim 6. (Original) The composition of claim 5 comprising a pharmacologically acceptable carrier.

Claims 7-19. (Canceled)

Claim 20. (New) The angiogenic composition of claim 2 wherein said other at least one angiogenic growth factor comprises bone-derived angiogenic proteins (BDAPs).

Claim 21. (New) The angiogenic composition of claim 2 wherein said other at least one angiogenic growth factor comprises vascular endothelial cell growth factor (VEGF).

Claim 22. (New) The angiogenic composition of claim 2 wherein said other at least one angiogenic growth factor comprises at least one peptide chosen from the group consisting of IGD (SEQ ID NO:1), GGIGDGG (SEQ ID NO:2), IGDIGD (SEQ ID NO:3), cyclic IGDIGD (SEQ ID NO:4), IGDS (SEQ ID NO:5), and IGDQ (SEQ ID NO:6).

Claim 23. (New) The composition of claim 2 comprising a pharmacologically acceptable carrier.

Claim 24. (New) The composition of claim 23 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.

Claim 25. (New) The composition of claim 23 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.

Claim 26. (New) The composition of claim 2 comprising an injectable solution.

Claim 27. (New) The composition of claim 23 wherein the injectable solution comprises polyvinylpyrrolidinone.

Claim 28. (New) The composition of claim 23 wherein the injectable solution comprises hydrochloric acid.

Claim 29. (New) The angiogenic composition of claim 5 comprising at least one angiogenic growth factor other than said at least one peptide.

Claim 30. (New) The angiogenic composition of claim 29 wherein said at least one angiogenic growth factor is chosen from the group consisting of bone-derived angiogenic proteins (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF- α), transforming growth factor-beta (TGF- β), and tumor necrosis factor-alpha (TNF- α).

Claim 31. (New) The angiogenic composition of claim 29 wherein said at least one angiogenic growth factor comprises bone-derived angiogenic proteins (BDAPs).

Claim 32. (New) The angiogenic composition of claim 29 wherein said at least one angiogenic growth factor comprises vascular endothelial cell growth factor (VEGF).

Claim 33. (New) The angiogenic composition of claim 29 wherein said at least one angiogenic growth factor comprises at least one peptide chosen from the group consisting of IGD (SEQ ID NO:1), GGIGDGG (SEQ ID NO:2), IGDIGD (SEQ ID NO:3), cyclic IGDIGD (SEQ ID NO:4), IGDS (SEQ ID NO:5), and IGDQ (SEQ ID NO:6).

Claim 34. (New) The composition of claim 5 comprising a pharmacologically acceptable carrier.

Claim 35. (New) The composition of claim 34 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.

Claim 36. (New) The composition of claim 34 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.

Claim 37. (New) The composition of claim 5 comprising an injectable solution.

Claim 38. (New) The composition of claim 37 wherein the injectable solution comprises polyvinylpyrrolidinone.

Claim 39. (New) The composition of claim 37 wherein the injectable solution comprises hydrochloric acid.

Claim 40. (New) The angiogenic composition of claim 5 wherein said matrix comprises a cell growth promoting matrix.